Scancell Holdings shares jump 9% following high-value licensing announcement
Portfolio Pulse from
Scancell Holdings shares rose 9% after announcing a licensing agreement with Genmab, potentially worth $630 million. The deal gives Genmab exclusive global rights to develop and commercialize a monoclonal antibody from Scancell's GlyMab platform.
December 04, 2024 | 9:15 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Scancell Holdings' shares increased by 9% following a licensing agreement with Genmab, potentially worth $630 million. This deal grants Genmab exclusive rights to a monoclonal antibody from Scancell's GlyMab platform.
The significant increase in Scancell's share price is directly linked to the high-value licensing agreement with Genmab, which is a positive development for the company. The potential $630 million in payments and the exclusive rights granted to Genmab are likely to boost investor confidence and interest in Scancell.
CONFIDENCE 95
IMPORTANCE 85
RELEVANCE 90